Market capitalization | $6.53m |
Enterprise Value | $5.34m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | negative |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-7.37m |
Free Cash Flow (TTM) Free Cash Flow | $-6.12m |
Cash position | $1.19m |
As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.
1 Analyst has issued a forecast Alzamend Neuro Inc:
1 Analyst has issued a forecast Alzamend Neuro Inc:
Jul '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -0.05 -0.05 |
67%
67%
|
|
EBITDA | -7.32 -7.32 |
52%
52%
|
EBIT (Operating Income) EBIT | -7.37 -7.37 |
52%
52%
|
Net Profit | -7.39 -7.39 |
52%
52%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Alzamend Neuro, Inc. is a preclinical stage biopharmaceutical company, which engages in the manufacture of pharmaceutical products. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders. The company was founded on February 26, 2016 by Milton C. Ault, III and is headquartered in Tampa, FL.
Head office | United States |
CEO | Stephan Jackman |
Employees | 7 |
Founded | 2016 |
Website | www.alzamend.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.